IMB 301
Alternative Names: IMB-301Latest Information Update: 06 Mar 2024
At a glance
- Originator IMBiologics
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 03 Jan 2024 Early research in Unspecified in South Korea (unspecified route) (IMBiologics pipeline, January 2024)